New insider activity at Guardant Health ( (GH) ) has taken place on March 19, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Director Tariq Musa of Guardant Health has recently sold 348 shares of the company’s stock in a transaction valued at $30,655, signaling a notable insider move that may draw attention from shareholders and market watchers alike.
Recent Updates on GH stock
Guardant Health shares saw positive sentiment after its Q4 earnings call highlighted strong revenue and test-volume growth, improving margins, and a clearer, though still investment-heavy, path toward profitability. Multiple firms raised price targets, citing robust execution in oncology and screening, better balance sheet strength, and a solid yet conservative 2026 outlook with significant Shield screening investment and upcoming catalysts.
Spark’s Take on GH Stock
According to Spark, TipRanks’ AI Analyst, GH is a Neutral.
The score is held back primarily by weak financial performance (large losses, ongoing cash burn, and balance-sheet strain with negative equity and higher debt). Offsetting this, the latest earnings call was constructive with strong 2026 growth guidance and improving cash burn trajectory, while technical signals are mixed-to-neutral and valuation remains challenged due to losses and no dividend support.
To see Spark’s full report on GH stock, click here.
More about Guardant Health
YTD Price Performance: -14.56%
Average Trading Volume: 1,911,773
Technical Sentiment Signal: Buy
Current Market Cap: $11.45B